In This Article:
-
U.S. Revenue: $310 million for full year 2024.
-
Q4 U.S. Net Sales for BRIUMVI: $103.6 million, 24% growth quarter-over-quarter.
-
Total Global Revenue: Approximately $329 million for full year 2024.
-
Net Income: Approximately $23 million or $0.15 per diluted share for both Q4 and full year 2024.
-
Operating Expenses: $51 million for Q4 and $206 million for full year 2024.
-
Cash Position: Approximately $311 million in cash equivalents and investment securities at the end of Q4 2024.
-
Gross Margin: Impacted by sales to NeuraxPharm, but expected to remain consistent otherwise.
-
2025 Revenue Guidance: Estimated $115 million in U.S. BRIUMVI net revenue for Q1 2025, with full year guidance of $525 million.
Release Date: March 03, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
TG Therapeutics Inc (NASDAQ:TGTX) reported U.S. revenues of $310 million for 2024, exceeding their target guidance, indicating strong market performance.
-
The company presented positive data from the enhanced trial, demonstrating the safety of a 30-minute maintenance infusion for BRIUMVI.
-
BRIUMVI's five-year follow-up data showed 92% of patients were free from disability progression, with a low annualized relapse rate.
-
The company expanded its patent portfolio, securing protection for BRIUMVI through 2042, strengthening its competitive position.
-
TG Therapeutics Inc (NASDAQ:TGTX) is exploring new markets, including Myasthenia gravis, and developing a subcutaneous formulation of BRIUMVI, which could expand their market reach.
Negative Points
-
The company faces competition from new entrants in the market, which could impact BRIUMVI's market share.
-
There is uncertainty regarding the final design and dosing regimen for the subcutaneous BRIUMVI trial, which could delay its development.
-
The cost of goods sold to partners outside the U.S. impacts the company's gross margin unfavorably.
-
Enrollment for the phase one study of azer-cel in progressive forms of multiple sclerosis has been slow, potentially delaying results.
-
The company anticipates increased operating expenses in 2025, which could impact profitability if not managed effectively.
Q & A Highlights
Q: Can you provide more color on the strong growth in January and February, and the 2025 guidance to exceed $525 million? Also, how do you see the role of the high-dose Ocrevus in the market? A: Our growth is driven by a broad set of customers, with significant enrollment in both academic and private clinic settings. Academic hospitals now account for the majority of our growth. This is due to factors like our five-year data, real-world experience, and expansion strategy. Regarding the high-dose Ocrevus, it depends on the profile, safety, and infusion experience, which we haven't seen much of yet.